However, there was a trend for differences in complete remission in patients with TN CLL (20% vs. 50%, respectively) and those with del(17p) and/or TP53 mutations (22% vs. 33%, respectively) [69]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.